Loading...

PE/Cyanine7 anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1-2_PECyanine7_IFN-y_Antibody_1_041124
PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with B220 (RA3-6B2) APC and XMG1.2 PE/Cyanine7
  • XMG1-2_PECyanine7_IFN-y_Antibody_1_041124
    PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with B220 (RA3-6B2) APC and XMG1.2 PE/Cyanine7
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
505825 25 µg 106€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505826 100 µg 243€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Additional Product Notes

BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  2. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  3. Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed
  4. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  5. Marchelletta RR, et al. 2021. J Clin Invest. 131:. PubMed
  6. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  7. Nakata J, et al. 2018. Oncotarget. 9:36029. PubMed
  8. He Y, et al. 2021. Infect Immun. 89:. PubMed
  9. Geng Z, et al. 2021. Nat Commun. 12:6584. PubMed
  10. Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
  11. Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed
  12. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  13. Baldwin SL, et al. 2021. PLoS One. 16:e0247990. PubMed
  14. He Y, et al. 2020. Sci Adv. 6:eaba7589. PubMed
  15. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  16. Harel M, et al. 2020. Cell. 179(1):236-250.e18.. PubMed
  17. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  18. Zhao B, et al. 2020. Nat Commun. 11:908. PubMed
  19. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  20. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  21. Saito S, et al. 2020. Nutrients. 12:. PubMed
  22. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  23. Kosack L, et al. 2017. Sci Rep. 7:11289. PubMed
  24. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  25. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  26. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  27. Linnerbauer M, et al. 2022. Front Immunol. 12:800128. PubMed
  28. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  29. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  30. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  31. Marangoni F, et al. 2021. Cell. . PubMed
  32. Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed
  33. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  34. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  35. Nagarajan D, et al. 2021. Immunol Cell Biol. 99:972. PubMed
  36. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  37. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  38. Glennie N, et al. 2015. J Exp Med. 212: 1405-1414. PubMed
  39. Dumas AA, et al. 2020. EMBO J. 39:e103790. PubMed
  40. Devos M, et al. 2020. J Exp Med. 217:00:00. PubMed
  41. Voisinne G, et al. 2022. Nat Immunol. 23:1355. PubMed
  42. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  43. Shiomi A, et al. 2014. J Immunol. 193:849. PubMed
  44. Sawant D, et al. 2014. J Immunol. 192:2904. PubMed
  45. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  46. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  47. Colliou N, et al. 2018. Gut Microbes. 9:279. PubMed
  48. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  49. Cho S, et al. 2017. Sci Rep. 7:35. PubMed
  50. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  51. Tello-Lafoz M, et al. 2021. Immunity. 54(5):1037-1054.e7. PubMed
  52. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
  53. Overacre-Delgoffe AE, et al. 2017. Cell. 169:1130. PubMed
  54. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  55. Xu S, et al. 2021. Immunity. . PubMed
  56. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  57. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  58. Jiang J, et al. 2017. Arthritis Res Ther. 10.1186/s13075-017-1261-9. PubMed
  59. Meadows D, et al. 2015. PLoS One. 10: 0143738. PubMed
  60. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  61. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  62. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  63. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  64. Silver J, et al. 2020. Methods Mol Biol. 2121:115. PubMed
  65. Stotesbury C, et al. 2020. J Immunol. 204:1582. PubMed
  66. Wang Y, et al. 2020. Cell Death Dis. 1.169444444. PubMed
  67. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  68. Wu B, et al. 2020. Int J Biol Sci. 16:1526. PubMed
  69. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  70. Saigusa R, et al. 2018. Arthritis Res Ther. 20:23. PubMed
  71. Xi‐Zhi J Guo et al. 2018. Immunity. 49(3):531-544 . PubMed
  72. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  73. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  74. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  75. Holm J, et al. 2015. PLoS One. 10:125495. PubMed
  76. Abhyankar MM, et al. 2018. NPJ Vaccines. 3:22. PubMed
  77. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  78. Friedman R, et al. 2014. Proc Natl Acad Sci U S A. 111:9223. PubMed
  79. Huang H, et al. 2021. Cell. 184(5):1245-1261.e21. PubMed
  80. Li C, et al. 2018. Cell. 174:285. PubMed
  81. Resende M, et al. 2019. J Immunol. 203:2451. PubMed
  82. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  83. Minns D, et al. 2021. Nat Commun. 12:1285. PubMed
  84. Dhar P, et al. 2021. Commun Biol. 4:905. PubMed
  85. Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
  86. Sun X, et al. 2021. Nature. 599:673. PubMed
  87. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  88. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  89. Sun X, et al. 2017. Microbes Infect. 10.1016/j.micinf.2017.08.007. PubMed
  90. Chen Y, et al. 2021. Nat Immunol. 22:996. PubMed
  91. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  92. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  93. Yu H, et al. 2021. Cell Death Dis. 13:1. PubMed
  94. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  95. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  96. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  97. Wen J, et al. 2015. J Pharmacol Sci. 128: 116-124. PubMed
  98. Imbratta C, et al. 2019. Sci Rep. 9:6135. PubMed
  99. Stotesbury C, et al. 2020. Aging Cell. 19:e13170. PubMed
  100. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  101. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  102. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  103. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  104. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  105. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  106. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  107. Jackson C, et al. 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed
  108. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  109. Zander R, et al. 2020. Immunity. 51(6):1028-1042.e4.. PubMed
  110. Wolf Y, et al. 2019. Cell. 179:219. PubMed
  111. Omenetti S, et al. 2019. Immunity. 51:77. PubMed
  112. Wang Y, et al. 2022. Nat Cell Biol. 24:230. PubMed
  113. Kalim KW, et al. 2021. Front Immunol. 12:726393. PubMed
RRID
AB_1595591 (BioLegend Cat. No. 505825)
AB_2295770 (BioLegend Cat. No. 505826)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11-30-2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account